Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Beijing Unveils Ambitious 2030 Blueprint for Global Biomedical Dominance
China has unveiled a 5-year plan to capture 25% of the global first-in-class drug market by 2030, heavily investing in AI, ADCs, and cell/gene therapies.
AI Reddit Analysis Reveals Hidden GLP-1 Side Effects Missing in Trials
An AI analysis of over 400,000 Reddit posts highlights overlooked real-world side effects of GLP-1 medications, such as fatigue and reproductive changes.
Oncodesign Services and Nexus BioQuest Partner on Preclinical Drug R&D
Oncodesign Services and Nexus BioQuest have formed a strategic partnership to provide integrated in vivo pharmacology and in vitro immunology CRO services.
FDA Approves Levacetylleucine as First Ataxia-Telangiectasia Treatment
The FDA has approved IntraBio's levacetylleucine (Aqneursa), the first targeted treatment for ataxia in adult and pediatric ataxia-telangiectasia patients.
FDA Approves Inluriyo and Verzenio Combo for Metastatic Breast Cancers
The FDA has approved Eli Lilly's Inluriyo and Verzenio combination therapy for adults with ESR1-mutated advanced or metastatic ER+/HER2- breast cancer.
ARDD 2026: Global Pharma and FDA Leaders Unite at Harvard for Longevity
The 13th ARDD 2026 meeting at Harvard gathers pharma, FDA, and biotech leaders to discuss longevity biotechnology, AI, and clinical trials this October.
GSK Bolsters Oncology Pipeline With $750M Chimagen TCE Licensing Deal
GSK acquires global rights to Chimagen Biosciences’ trispecific T-cell engager for multiple myeloma in a $750M deal, reinforcing its oncology pipeline.
FDA Launches Expedited IND Pilot Program to Accelerate Phase 1 Trials
The FDA's new Expedited IND pilot program pairs sponsors with research institutions using a rolling submission process to accelerate Phase 1 clinical trials.
FDA Approves Nuvation Bio's IBTROZI sNDA for ROS1-Positive Lung Cancer
Nuvation Bio secures FDA approval for its supplemental New Drug Application for IBTROZI (taletrectinib) to treat ROS1-positive non-small cell lung cancer.
SpliSense Begins Phase IIb Clinical Trial of SPL84 for Cystic Fibrosis
SpliSense launches a Phase IIb clinical trial for SPL84, an inhaled antisense oligonucleotide therapy targeting specific cystic fibrosis gene mutations.
SL Science Analysis: A $1.15 Billion Valuation on Preclinical Promises
SL Science holds a $1.15B valuation based entirely on unproven preclinical Gamma Delta T cell therapy. Discover the risks and why analysts rate it a Sell.
FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy Therapy
The FDA approved Scholar Rock's Isembyld, the first muscle-targeted therapy for spinal muscular atrophy, culminating a challenging regulatory journey.
1
2
3
4
5
6
7
